Pfizer Inc. (NYSE:PFE) Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 12.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 649,913 shares of the biopharmaceutical company's stock after selling 96,575 shares during the period. Mackenzie Financial Corp's holdings in Pfizer were worth $17,242,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Rialto Wealth Management LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer in the 4th quarter worth approximately $27,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer in the 4th quarter worth approximately $31,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer in the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on PFE shares. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Price Performance

NYSE PFE traded up $0.26 during mid-day trading on Thursday, hitting $23.44. The stock had a trading volume of 26,040,087 shares, compared to its average volume of 41,037,838. The firm's 50 day moving average is $23.22 and its 200 day moving average is $25.11. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $133.26 billion, a price-to-earnings ratio of 16.62, a PEG ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period last year, the company earned $0.82 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.34%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.